A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors MedImmune
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 08 Jul 2016 Status changed from active, no longer recruiting to completed.
- 20 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.